S15 Ep43: Medical Crossfire®: The Who, When, and How of TROP2-Targeting ADCs, ICIs, and PARP Inhibition in Triple-Negative Breast Cancer
OncLive® On Air
00:00
SASC‑IO and combining SG with pembrolizumab
Heather McArthur describes trials testing sacituzumab govitecan with pembrolizumab to stimulate responses in PD‑L1 negative disease.
Play episode from 10:36
Transcript
